CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

The CHMP recommendation is based on the Phase III PINNACLE programme, which demonstrated the efficacy and safety of Bevespi Aerosphere and involved more than 5,000 patients with moderate to very severe COPD.

Dr Colin Reisner, Head of Respiratory, Global Medicines Development, said: “Bevespi Aerosphere is the only fixed-dose long-acting muscarinic antagonist/long-acting beta2-agonist that is delivered in a pressurised metered-dose inhaler. Today’s positive CHMP opinion means COPD patients in Europe are one step closer to having this new dual bronchodilator treatment available to them.”

Bevespi Aerosphere is approved in the US, Canada and Australia as a dual bronchodilator for the long-term maintenance treatment of COPD.

About COPD

COPD is a progressive disease which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness.1 It affects an estimated 384 million people worldwide and is predicted to be the third leading cause of death by 2020.1,2 Improving lung function, reducing exacerbations and managing daily symptoms such as breathlessness are important to the management of COPD.1

About the Phase III PINNACLE programme

PINNACLE 1, 2 and 4 were randomised, double-blinded, multi-centre, placebo-controlled trials conducted over 24 weeks, which compared the efficacy and safety of Bevespi Aerosphere administered twice daily via a pMDI, compared to its monotherapy components (glycopyrronium and formoterol fumarate) and to placebo.3,4,5 In PINNACLE 1, open-label tiotropium was included as an active control.3 PINNACLE 3 was a multi-centre, randomised, double-blinded, parallel-group, chronic-dosing, active-controlled, 28-week safety extension trial of PINNACLE 1 and 2, which evaluated the long-term safety, tolerability, and efficacy of Bevespi Aerosphere administered twice daily via a pMDI compared to its monotherapy components.6 All the trials were conducted in patients with moderate to very severe COPD.

About Bevespi Aerosphere

Bevespi Aerosphere is a fixed-dose dual bronchodilator combining glycopyrronium, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-agonist (LABA). Bevespi Aerosphere is the only LAMA/LABA with Aerosphere Delivery Technology. Results from an imaging trial have shown that Bevespi Aerosphere effectively delivers medicine to both the large and small airways.7 Aerosphere Delivery Technology is also the platform for other potential new medicines including PT010, AstraZeneca’s triple combination of budesonide/glycopyrronium/formoterol fumarate.

About AstraZeneca in Respiratory Disease

Respiratory disease is one of AstraZeneca’s main therapy areas, and the Company has a growing portfolio of medicines that reached more than 18 million patients in 2017. AstraZeneca’s aim is to transform asthma and COPD treatment through inhaled combinations at the core of care, biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification.

The Company is building on a 40-year heritage in respiratory disease and AstraZeneca’s capability in inhalation technology spans pressurised metered-dose inhalers and dry powder inhalers, as well as the Aerosphere Delivery Technology. The company also has a growing portfolio of respiratory biologics including Fasenra (anti-eosinophil, anti-IL-5rɑ), approved for severe eosinophilic asthma and in development for severe nasal polyposis, and tezepelumab (anti-TSLP), which has been granted Breakthrough Therapy designation by the US Food and Drug Administration in patients with severe asthma and is in Phase III trials. AstraZeneca’s research is focused on addressing underlying disease drivers focusing on the lung epithelium, lung immunity and lung regeneration.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit http://www.astrazeneca.com/ and follow us on Twitter @AstraZeneca.

 

Media Relations

 

 

 

Karen Birmingham

UK/Global

+44 203 749 5634

 

Rob Skelding

UK/Global

+44 203 749 5821

 

Matt Kent

UK/Global

+44 203 749 5906

 

Gonzalo Viña

UK/Global

+44 203 749 5916

 

Jennifer Hursit

UK/Global

+44 203 749 5762

 

Jacob Lund

Sweden

+46 8 553 260 20

 

Michele Meixell

US

+1 302 885 2677

 

 

 

 

  Investor Relations

 

 

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

 

Henry Wheeler

Oncology

+44 203 749 5797

 

Christer Gruvris

Cardiovascular; Metabolism

+44 203 749 5711

 

Nick Stone

Respiratory; Renal

+44 203 749 5716

 

Josie Afolabi

Other

+44 203 749 5631

 

Craig Marks

Finance; Fixed Income

+44 7881 615 764

 

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

 

US toll-free

 

+1 866 381 7277

             

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

References

1.      GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. [Online]. Available at: http://goldcopd.org. Last accessed: October 2018.

2.      Adeloye D, Chua S, Lee C, et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015; 5 (2): 020415.

3.      Clinicaltrials.gov. Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1). [Online]. Available at: https://clinicaltrials.gov/ct2/show/NCT01854645. Last accessed: October 2018.

4.      Clinicaltrials.gov. Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2). [Online]. Available at: https://clinicaltrials.gov/ct2/show/NCT01854658. Last accessed: October 2018.

5.      AstraZeneca plc. Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD. [Online]. Available at: https://www.astrazeneca.com/media-centre/press-releases/2017/bevespi-aerosphere-demonstrates-statistically-significant-improvement-in-lung-function-in-patients-with-copd-25092017.html Last accessed: October 2018

6.      Clinicaltrials.gov. Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3). [Online]. Available at: https://clinicaltrials.gov/ct2/show/NCT01970878. Last accessed: October 2018.

7.      AstraZeneca. Aerosphere Delivery Technology – Global Core Claims Guide.

tags

  • Andningsvägar